South Plainfield, NJ, United States

Prolong Pharmaceuticals

www.prolongpharma.com
South Plainfield, NJ, United States
SEARCH FILTERS
Time filter
Source Type

SMi Reports: Interview released with Glenn Kazo, President and Chief Operating Officer from Prolong Pharmaceuticals LLC. London, United Kingdom, July 27, 2017 --( Prolong Pharmaceuticals is a privately held company with portfolio of hematology and oncology products in clinical development. With over 25 years of experience, Glenn Kazo has been very active in the advancement of Biosimilars and BioBetters, both as an industry speaker and in leading several drug development programs. Throughout his career, Glenn has continued an active consulting practice, advising biopharma clients and venture capital firms on corporate strategy and development. With a focus on Biobetters, his presentation will explore developing the next generation anti-neuropenic factor. Neulasta is one of the most desirable targets for biosimilar development. Glen’s talk will discuss ongoing technical and market challenges to biosimilar versions of Neulasta, neutropenia prevention vs treatment; and the commercial approach to developing ANF-RhoTM. In the run-up to the event, SMi Group caught up with Glen to discuss in industry developments and on-going challenges in Biosimilars. “Beginning in 2012, I gave a series of talks called Why ‘BioDifferent Equals BioBetter.’ The underlying theme was that it is much easier to prove that products are different rather than to prove that products are similar. It wasn’t a popular concept – but companies are now finding out that regulators and customers hold a very high standard of ‘similar’ and an even higher standard for 'interchangeable.'” The full interview is available to read in the event download centre at http://www.smi-online.co.uk/goto/2017biosimilars7.asp#tab_downloads with further Q&A’s from Celltrion and Bioceros. SMi’s 8th Annual Biosimilars & Biobetters event will take place on 27th and 28th September 2017 at the Holiday Inn Kensington Forum, London UK. More information and a detailed agenda featuring talks from Boehringher Ingelheim, Celltrion Healthcare, Gedeon Richter, Teva Pharmaceuticals, Merck Group, QuintilesIMS and the Norwegian Medicines Agency is available at http://www.biosimilars-europe.com Contact Information: For media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk For all other enquires contact the team on Tel: +44 (0)20 7827 6000 or email events@smi-online.co.uk About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk London, United Kingdom, July 27, 2017 --( PR.com )-- SMi Group have released an interview with Glenn Kazo, President and Chief Operating Officer from Prolong Pharmaceuticals, ahead of his presentation at the 8th annual industry summit on Biosimilars & Biobetters this September.Prolong Pharmaceuticals is a privately held company with portfolio of hematology and oncology products in clinical development. With over 25 years of experience, Glenn Kazo has been very active in the advancement of Biosimilars and BioBetters, both as an industry speaker and in leading several drug development programs. Throughout his career, Glenn has continued an active consulting practice, advising biopharma clients and venture capital firms on corporate strategy and development.With a focus on Biobetters, his presentation will explore developing the next generation anti-neuropenic factor. Neulasta is one of the most desirable targets for biosimilar development. Glen’s talk will discuss ongoing technical and market challenges to biosimilar versions of Neulasta, neutropenia prevention vs treatment; and the commercial approach to developing ANF-RhoTM.In the run-up to the event, SMi Group caught up with Glen to discuss in industry developments and on-going challenges in Biosimilars.“Beginning in 2012, I gave a series of talks called Why ‘BioDifferent Equals BioBetter.’ The underlying theme was that it is much easier to prove that products are different rather than to prove that products are similar. It wasn’t a popular concept – but companies are now finding out that regulators and customers hold a very high standard of ‘similar’ and an even higher standard for 'interchangeable.'”The full interview is available to read in the event download centre at http://www.smi-online.co.uk/goto/2017biosimilars7.asp#tab_downloads with further Q&A’s from Celltrion and Bioceros.SMi’s 8th Annual Biosimilars & Biobetters event will take place on 27th and 28th September 2017 at the Holiday Inn Kensington Forum, London UK.More information and a detailed agenda featuring talks from Boehringher Ingelheim, Celltrion Healthcare, Gedeon Richter, Teva Pharmaceuticals, Merck Group, QuintilesIMS and the Norwegian Medicines Agency is available at http://www.biosimilars-europe.comContact Information:For media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.ukFor all other enquires contact the team on Tel: +44 (0)20 7827 6000 or email events@smi-online.co.ukAbout SMi Group:Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk Click here to view the list of recent Press Releases from SMi Group


This report provides an overview of the transplantation pipeline landscape, specifically covering drugs used to prevent and treat organ rejection and graft-versus-host disease. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for graft-versus-host disease (GVHD), and the rejection of bone, liver, kidney, lung and heart transplants. Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body. There are a total of 121 products in development for this indication, by 83 companies and 21 academic institutions. Key companies operating in this pipeline space include Novartis and Abbvie. GVHD is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. There are a total of 108 products in development for this indication, by 76 companies and 19 academic institutions. Similarly to the bone marrow transplantation space, key companies operating in this pipeline space include Novartis and Abbvie. Following a liver transplant, the immune system may consider the transplanted liver as foreign and may work against it. Patients may hence develop complications and ultimately reject the new organ. There are a total of ten products in development for this indication, by seven companies and two academic institutions. Kidney transplantation is a therapy performed to replace a diseased kidney with a healthy kidney from another person. Risk factors associated with transplantation are bleeding, infection, blockage of the blood vessels to the new kidney, leakage of urine or blockage of urine in the ureter and initial lack of function of the new kidney. There are a total of 39 products in development for this indication, by 33 companies and two academic institutions. Key companies operating in this pipeline space include Astellas, GlaxoSmithKline, Hillhurst Biopharmaceuticals and Kyowa Hakko Kirin. Lung transplantation is a therapy used in various lung diseases. Lung transplant replaces an injured or diseased lung with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted lung as foreign and may work against it. There are a total of ten products in development for this indication, by eight companies. Key companies operating in this pipeline space include Quark Pharmaceuticals and Radikal Therapeutics, both of which are fielding two products in this area each. Finally, heart transplantation is a therapy used in various heart diseases. Heart transplant replaces an injured or diseased heart with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted heart as foreign and may work against it. There are a total of seven products in development for this indication, all of which are in the Preclinical stage, by five companies, Of these products, Astellas are fielding three. A wide range of targets, including integrins, chemokine receptors, protein kinases and cadherins are being developed, with no particular class of target predominating in terms of pipeline volume. However, there is a clear trend towards immune system molecular targets being studied, reflecting the underlying immune-based pathophysiology of these indications. - Bone Marrow Transplant Rejection - Graft Versus Host Disease (GVHD) - Liver Transplant Rejection - Kidney Transplant Rejection - Lung Transplant Rejection - Heart Transplant Rejection Key Topics Covered: 1. Research Report Guidance 2. Executive Summary 3. Introduction 4. Transplantation Report Coverage 5. Therapeutics Development 6. Therapeutics Assessment 7. Companies Involved in Therapeutics Development 8. Dormant Projects 9. Discontinued Products 10. Product Development Milestones 11. Appendix Companies Mentioned - AbGenomics International Inc - AbbVie Inc - Actelion Ltd - Alexion Pharmaceuticals Inc - Allergan Plc - Amgen Inc - Amunix Operating Inc - AnaptysBio Inc - Angion Biomedica Corp - Apceth Biopharma GmbH - Apellis Pharmaceuticals Inc - Apeptico Forschung und Entwicklung GmbH - Aptevo Therapeutics Inc - ArGEN-X BV - Astellas Pharma Inc - Athersys Inc - Bellicum Pharmaceuticals Inc - Bio-Cancer Treatment International Ltd - Biogen Inc - Bristol-Myers Squibb Company - CSL Ltd - Cantex Pharmaceuticals Inc - Capricor Therapeutics Inc - Catalyst Biosciences Inc - Cell Source Inc - Cell2B Advanced Therapeutics SA - CellECT Bio Inc - Cleveland BioLabs Inc - Commence Bio Inc - Compugen Ltd - Conatus Pharmaceuticals Inc - Corline Biomedical AB - Cynata Therapeutics Limited - Cynata Therapeutics Ltd - Cytodyn Inc - Dompe Farmaceutici SpA - Dr. Falk Pharma GmbH - Escape Therapeutics Inc - F. Hoffmann-La Roche Ltd - Fate Therapeutics Inc - Generon (Shanghai) Corp Ltd - Gilead Sciences Inc - GlaxoSmithKline Plc - Grifols SA - Hansa Medical AB - Heat Biologics Inc - Immunomedics Inc - Incyte Corp - Jazz Pharmaceuticals Plc - Kadmon Corp LLC - Kamada Ltd - Kiadis Pharma NV - Kymab Ltd - Kyorin Pharmaceutical Co Ltd - Kyowa Hakko Kirin Co Ltd - MacroGenics Inc - Magnus Life Ltd - Mallinckrodt Plc - Medsenic - Mesoblast Ltd - Millennium Pharmaceuticals Inc - Nektar Therapeutics - Neovii Pharmaceuticals AG - Nohla Therapeutics Inc - Noorik Biopharmaceuticals AG - Novartis AG - Noxxon Pharma AG - OSE Immunotherapeutics - OncoImmune Inc - Opsona Therapeutics Ltd - Pfizer Inc - Pharmicell Co Ltd - Pharming Group NV - Pluristem Therapeutics Inc - Prolong Pharmaceuticals LLC - Quark Pharmaceuticals Inc - Quark Pharmaceuticals Inc - REGiMMUNE Corp - RedHill Biopharma Ltd - Sanofi - Sarepta Therapeutics Inc - Seattle Genetics Inc - Seres Therapeutics Inc - Shire Plc - Sigmoid Pharma Ltd - Synedgen Inc - TC BioPharm Ltd - Taiga Biotechnologies Inc - Takeda Pharmaceutical Company Ltd - Targazyme Inc - Tiziana Life Sciences Plc - TxCell SA - United BioPharma Inc - VBI Vaccines Inc - Vault Pharma Inc - XL-protein GmbH - Xenikos BV - ZIOPHARM Oncology Inc For more information about this report visit https://www.researchandmarkets.com/research/5mszsg/transplantation Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716


Celltrion Healthcare Discuss Biosimilar Drug Approval and Look Ahead Into the Patent Expiry of Top Selling Biologics London, United Kingdom, June 28, 2017 --( Highlights from the talk presented by HoUng Kim, Division Head for Strategy and Operations include: The Challenges of Gaining Approval: Attendees will leverage stringent standard criteria to overcome challenges in regulation as Celltrion draw from experience on the successful approval of two biosimilar drugs. Publishing Data: The presentation will cover ARD requirement on sensitivity analysis and discuss ways in which Celltrion demonstrated a similar response rate regardless of different statistical approaches. Future Landscape of Biosimialrs: The talk will look ahead into the tremendous expansion expected in biosimilars surrounding the patent expiry of top selling biologics in coming years. Progressive outlook will also be given on the industry shift towards personalised and convenient treatments. Other speakers on the panel for 2017 will include Boehringer Ingelheim; Norwegian Medicines Agency; QuintilesIMS; Gedeon Richter; Teva Pharmaceuticals; Biocon; Prolong Pharmaceuticals; Merck Group and Lupin Europe. Further details are available online at www.biosimilars-europe.com Biosimilars & Biobetters 27th & 28th September 2017 Holiday Inn Kensington Forum, London UK Contact Information: For media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk For all other enquires contact the team on Tel: +44 (0)20 7827 6000 or email events@smi-online.co.uk About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk London, United Kingdom, June 28, 2017 --( PR.com )-- SMi Group are delighted to welcome the expertise of Celltrion Healthcare when they present a keynote address at the 8th annual industry summit on Biosimilars & Biobetters this September.Highlights from the talk presented by HoUng Kim, Division Head for Strategy and Operations include:The Challenges of Gaining Approval: Attendees will leverage stringent standard criteria to overcome challenges in regulation as Celltrion draw from experience on the successful approval of two biosimilar drugs.Publishing Data: The presentation will cover ARD requirement on sensitivity analysis and discuss ways in which Celltrion demonstrated a similar response rate regardless of different statistical approaches.Future Landscape of Biosimialrs: The talk will look ahead into the tremendous expansion expected in biosimilars surrounding the patent expiry of top selling biologics in coming years. Progressive outlook will also be given on the industry shift towards personalised and convenient treatments.Other speakers on the panel for 2017 will include Boehringer Ingelheim; Norwegian Medicines Agency; QuintilesIMS; Gedeon Richter; Teva Pharmaceuticals; Biocon; Prolong Pharmaceuticals; Merck Group and Lupin Europe.Further details are available online at www.biosimilars-europe.comBiosimilars & Biobetters27th & 28th September 2017Holiday Inn Kensington Forum, London UKContact Information:For media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.ukFor all other enquires contact the team on Tel: +44 (0)20 7827 6000 or email events@smi-online.co.ukAbout SMi Group:Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk Click here to view the list of recent Press Releases from SMi Group


-- SMi Group are delighted to welcome the expertise ofwhen they present a keynote address at the 8th annual industry summit onthis September.Highlights from the talk presented by HoUng Kim, Division Head for Strategy and Operations include:The Challenges of Gaining Approval: Attendees will leverage stringent standard criteria to overcome challenges in regulation as Celltrion draw from experience on the successful approval of two biosimilar drugs.Publishing Data: The presentation will cover ARD requirement on sensitivity analysis and discuss ways in which Celltrion demonstrated a similar response rate regardless of different statistical approaches.Future Landscape of Biosimialrs:The talk will look ahead into the tremendous expansion expected in biosimilars surrounding the patent expiry of top selling biologics in coming years. Progressive outlook will also be given on the industry shift towards personalised and convenient treatments.Other speakers on the panel for 2017 will include Boehringer Ingelheim; Norwegian Medicines Agency; QuintilesIMS;Gedeon Richter; Teva Pharmaceuticals;Biocon; Prolong Pharmaceuticals;Merck Group and Lupin Europe.Further details are available online at https://www.smi- online.co.uk/ pharmaceuticals/ uk/biosimila... Biosimilars & Biobetters27th & 28th September 2017Holiday Inn Kensington Forum, London UK--end –Contact Information:For media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.ukFor all other enquires contact the team on Tel: +44 (0)20 7827 6000 or email events@smi-online.co.ukAbout SMi Group:Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi- online.co.uk


Patent
Prolong Pharmaceuticals | Date: 2016-11-22

The invention provides compositions containing hemoglobin, particularly PEGylated hemoglobin. The PEGylated hemoglobin molecule is capable of transferring oxygen or carbon monoxide bound thereto to a tissue with which it is in proximity. Exemplary PEGylated hemoglobin formulations of the invention are virally inactivated. Various compositions of the invention include deoxygenated hemoglobin, which may be conjugated with one or more water-soluble polymer. PEGylated hemoglobin includes those species in which the iron atom of the hemoglobin molecule is not bound to oxygen or any other species, and hemoglobin molecules in which a species other than oxygen, e.g., carbon monoxide, is bound to the iron atom. The compositions of the invention are formulated as hypo-, iso- or hypertonic solutions of the PEGylated hemoglobin. The compositions are of use to treat and/or ameliorate disease, injury and insult by providing for the oxygenation of tissues and/organs.


— Pipeline report on Sickle Cell Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Sickle Cell Disease (Hematological Disorders). The complete is analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Browse the 54 Tables and 11 Figures, 36 Company Profiles, Spread across 191 Pages Report Available at http://www.reportsnreports.com/reports/992906-sickle-cell-disease-pipeline-review-h1-2017.html . Sickle Cell Disease - Companies Involved in Therapeutics Development - Acceleron Pharma Inc, Addex Therapeutics Ltd, Addmedica SAS, Advinus Therapeutics Ltd, Alnylam Pharmaceuticals Inc, Angiocrine Bioscience Inc, ArQule Inc, Bio Products Laboratory Ltd, Bioverativ Inc, bluebird bio Inc, Bristol-Myers Squibb Company, Calimmune Inc, CRISPR Therapeutics, CSL Ltd 35,Editas Medicine Inc, Errant Gene Therapeutics LLC, Gamida Cell Ltd, Genethon SA, Gilead Sciences Inc, Global Blood Therapeutics Inc, Incyte Corp, Johnson & Johnson, La Jolla Pharmaceutical Company, MaxCyte Inc, Merck & Co Inc, Modus Therapeutics Holding AB, Morphogenesis Inc, NKT Therapeutics Inc, Novartis AG, Orphagen Pharmaceuticals Inc, Pfizer Inc, Prolong Pharmaceuticals LLC, Protagonist Therapeutics Inc, ReveraGen BioPharma Inc, Sancilio & Company Inc, Sangamo Therapeutics Inc. Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. Treatment includes antibiotics, pain relievers, blood transfusion and stem cell transplant. The Sickle Cell Disease (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sickle Cell Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 5, 9, 27, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 2 molecules, respectively. Place Order to This Report at http://www.reportsnreports.com/purchase.aspx?name=992906 Sickle Cell Disease (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Scope • The pipeline guide provides a snapshot of the global therapeutic landscape of Sickle Cell Disease (Hematological Disorders). • The pipeline guide reviews pipeline therapeutics for Sickle Cell Disease (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Sickle Cell Disease (Hematological Disorders) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Sickle Cell Disease (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Sickle Cell Disease (Hematological Disorders) About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. For more information, please visit http://www.reportsnreports.com/reports/992906-sickle-cell-disease-pipeline-review-h1-2017.html


The Global Hemoglobinopathie market is accounted for $4.6 billion in 2015 and is expected to reach $8.99 billion by 2022 growing at a CAGR of 10.0% from 2015 to 2022. Increasing incidences of hemoglobin disorders with strong product portfolio for sickle cell anemia such as HQK-1001 and Luspatercept, government’s awareness programs and advanced diagnostics and therapeutics will fuel the market growth. Research & development and growth across developed and developing economies will provide opportunity for the market growth. Instrumentation cost and expertise required for LC MS/MS, molecular identification of the alpha and beta chain mutations are some of the factors that impede the market growth. Hydroxyurea was one of the dominating segments followed by Thalassemia and is estimated to grow at lucrative growth rate. Blood tests and pre-implant genetic testing is anticipated to grow further during forecast period. The market for blood transfusion was the largest with revenues in therapeutic segment. North America dominated the overall market. Africa, Asia Pacific and the Mediterranean regions are projected to show profitable growth. Some of the key players in global Hemoglobinopathie market are Gamida Cell,Alnylam Pharmaceuticals, Biogen Idec, Genetix Pharmaceuticals, Global Blood Therapeutics Inc., Pfizer Inc., Mast Therapeutics, Emmaus Life Sciences, Inc., Prolong Pharmaceuticals, Celgene Corporation, HemaQuest Pharmaceuticals, Sangamo BioSciences Inc, Cancer Therapeutics CRC Pty Ltd, Datar Genetics Limited, Optinova Ab, Anthera Pharmaceuticals and AcceleronPharma. Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements For more information, please visit https://www.wiseguyreports.com/sample-request/674249-haemoglobinopathies-global-market-outlook-2016-2022


Patent
Prolong Pharmaceuticals | Date: 2013-06-21

The invention provides compositions containing hemoglobin, particularly PEGylated hemoglobin. The PEGylated hemoglobin molecule is capable of transferring oxygen or carbon monoxide bound thereto to a tissue with which it is in proximity. Exemplary PEGylated hemoglobin formulations of the invention are virally inactivated. Various compositions of the invention include hemoglobin, which may be conjugated with one or more water-soluble polymer. PEGylated hemoglobin includes those species in which the iron atom of the hemoglobin molecule is not bound to oxygen or any other species, and hemoglobin molecules in which a species other than oxygen, e.g., carbon monoxide, is bound to the iron atom. The compositions of the invention are formulated as hypo-, iso- or hypertonic solutions of the PEGylated hemoglobin. The compositions are of use to treat and/or ameliorate disease, injury and insult by providing for the oxygenation of tissues and/organs.


Patent
Prolong Pharmaceuticals | Date: 2016-06-13

This invention relates to novel PEGx-GCSF conjugates, wherein x is the amount of PEG per GCSF and ranges from 4 to 8. The invention also relates to PEG[x]-GCSF populations of individual PEGx-GCSF conjugates, wherein [x] is the average amount of PEG per GCSF of the population and is 4 or greater. The inventive compositions have unexpected therapeutic efficacy, while avoiding or substantially reducing the likelihood of adverse side effects.


Patent
Prolong Pharmaceuticals | Date: 2014-08-04

The invention provides compositions containing hemoglobin, particularly PEGylated hemoglobin. The PEGylated hemoglobin molecule is capable of transferring oxygen or carbon monoxide bound thereto to a tissue or red blood cells with which it is in proximity. Exemplary PEGylated hemoglobin formulations of the invention are virally inactivated. Various compositions of the invention include hemoglobin, which may be conjugated with one or more water-soluble polymer. PEGylated hemoglobin includes those species in which the iron atom of the hemoglobin molecule is not bound to oxygen or any other species, and hemoglobin molecules in which a species other than oxygen, e.g., carbon monoxide, is bound to the iron atom. The compositions of the invention are formulated as hypo-, iso- or hypertonic solutions of the PEGylated hemoglobin. The compositions are of use to treat and/or ameliorate disease, injury and insult by providing for the oxygenation of tissues and/organs.

Loading Prolong Pharmaceuticals collaborators
Loading Prolong Pharmaceuticals collaborators